Company intelligence / Profile preview

NanoThea

Warsaw, Poland

Ownership: Private
Employees: ~15
Development stage: Other

Overview

NanoThea is a Polish biotechnology company specializing in the development of targeted radiopharmaceuticals for oncology. The company utilizes a proprietary nanoparticle-based platform to deliver diagnostic and therapeutic isotopes specifically to cancer cells, minimizing side effects on healthy tissue. Their lead program, NT-001, focuses on prostate-specific membrane antigen (PSMA) for the management of prostate cancer. NanoThea aims to provide a theranostic approach, combining precise imaging with effective radionuclide therapy. The company is currently in the pre-clinical stage, advancing its pipeline toward first-in-human trials.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalNanoparticle
Industry: Biotech

Beyond the preview

Go deeper on NanoThea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoThea.

Explore the full profile